| 09/29/2026 3:10 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/08/2026 3:38 PM | Dyne Therapeutics (1818794) Subject Kerr Douglas (1814189) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/08/2026 3:39 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/08/2026 3:13 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/08/2026 3:14 PM | Dyne Therapeutics (1818794) Issuer Kerr Douglas (1814189) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/08/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Friedl-Naderer Johanna (1915598) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/17/2026 4:30 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/17/2026 3:06 PM | Dyne Therapeutics (1818794) Issuer Lucera Erick (1697616) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/17/2026 3:07 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/14/2026 4:46 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/14/2026 4:47 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Get the Latest News and Ratings for DYN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 08/14/2026 4:47 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:36 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:36 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:36 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:03 PM | Dyne Therapeutics (1818794) Subject Kerr Douglas (1814189) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:03 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 4:04 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 3:51 PM | Atlas Venture Fund XI, L.P. (1708269) Filed by Dyne Therapeutics (1818794) Subject | Form SCHEDULE 13G/A | |
| 08/13/2026 11:47 AM | Dyne Therapeutics (1818794) Subject Janus Henderson Group Ltd. (1274173) Filed by | Form SCHEDULE 13G/A | |
| 08/06/2026 9:20 AM | Dyne Therapeutics (1818794) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G/A | |
| 07/22/2026 4:19 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/22/2026 4:21 PM | Dyne Therapeutics (1818794) Filer | Form 424B5 | |
| 07/21/2026 4:22 PM | Dyne Therapeutics (1818794) Filer | Form 424B5 | |
| 07/20/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/08/2026 4:35 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/07/2026 4:05 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:05 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:06 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/07/2026 4:06 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:17 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:17 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/06/2026 4:17 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/30/2026 6:05 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/29/2026 4:49 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:50 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/29/2026 4:50 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:04 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 7:40 AM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
How Elon’s Empire Ends (and how to profit) (Ad) Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs.
These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days. See Chaikin's full research and the company name here |
| 06/25/2026 4:28 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2026 4:29 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2026 4:29 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/25/2026 4:11 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:32 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:33 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 4:36 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/24/2026 3:27 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/23/2026 5:25 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 5:26 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 5:19 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 3:05 PM | Dyne Therapeutics (1818794) Issuer Greene Barry E (1291963) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 06/23/2026 3:07 PM | Dyne Therapeutics (1818794) Issuer Greene Barry E (1291963) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/17/2026 3:03 PM | Dyne Therapeutics (1818794) Subject ForDyne B.V. (2019392) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/17/2026 3:07 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/09/2026 4:09 PM | Dyne Therapeutics (1818794) Issuer Stehman-Breen Catherine (1702233) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:12 PM | Dyne Therapeutics (1818794) Issuer Incerti Carlo (1915358) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:12 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:13 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:13 PM | Dyne Therapeutics (1818794) Issuer Lubner David Charles (1572000) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:15 PM | Dyne Therapeutics (1818794) Issuer HURWITZ EDWARD (1211840) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:06 PM | Dyne Therapeutics (1818794) Issuer Posner Brian S (1372455) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/08/2026 3:05 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/03/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/15/2026 11:36 AM | Dyne Therapeutics (1818794) Subject JANUS HENDERSON GROUP PLC (1274173) Filed by | Form SCHEDULE 13G/A | |
| 05/14/2026 3:04 PM | Dyne Therapeutics (1818794) Issuer Kerr Douglas (1814189) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/14/2026 3:05 PM | Dyne Therapeutics (1818794) Issuer Friedl-Naderer Johanna (1915598) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/13/2026 3:55 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/13/2026 3:57 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 6:25 AM | Dyne Therapeutics (1818794) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/11/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/06/2026 4:09 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/06/2026 3:42 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:42 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:43 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 10:13 AM | Dyne Therapeutics (1818794) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G | |
| 05/05/2026 3:36 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/05/2026 3:36 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/05/2026 3:37 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 4:00 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/30/2026 4:22 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/28/2026 3:56 PM | Dyne Therapeutics (1818794) Issuer Lubner David Charles (1572000) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/28/2026 3:42 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:43 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Trump's New Dollar (Ad) Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening.
The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result. Watch the free briefing and see the three steps to prepare today |
| 04/28/2026 3:43 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:44 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 5:15 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/27/2026 3:48 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:48 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:48 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:49 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:45 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:46 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |